Novo Nordisk A/S vs Berkshire Hathaway Inc
A head-to-head of Novo Nordisk A/S (NVO) and Berkshire Hathaway Inc (BRK-A) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | NVO | BRK-A |
|---|---|---|
| Market Cap | $182.56B | $1.03T |
| P/E (TTM) | 1.75 | 15.41 |
| Forward P/E | 12.24 | 21.10 |
| P/S | 0.59 | 2.78 |
| P/B | 0.92 | 1.44 |
| EV/EBITDA | 8.12 | 0.00 |
| Dividend Yield | 29.22% | — |
| Profit Margin | 33.14% | 18.01% |
| Gross Margin | 80.98% | 23.63% |
| Operating Margin | 41.30% | 16.03% |
| Revenue Growth (YoY) | -7.63% | -3.94% |
| FCF Yield | 15.88% | 2.43% |
| Debt / Equity | 67.49 | 19.38 |
| Current Ratio | 0.80 | 6.75 |
Share:
Compare Novo Nordisk A/S with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.